Top Management Presentation Financial Results of FY2018 Q1
(April 1 - June 30, 2018)

from the beginning

Top Management Presentation Financial Results of FY2018 Q1 (April 1 - June 30, 2018)

Forward-Looking Statements

Agenda

FY2018 Q1 Financial Results

Overview of FY2018 Q1 Results

Revenue

Operating Profit

Profit Attributable to Owners of the Company

Revenue: Major Business Units (incl. Forex Impact)

Revenue: Major Products in Japan

Business Update

Lixiana: Growth in Japan

Japan: Efforts for Cancer Pain

Transfer of Long-listed Products

LPI: Growth of Iron Franchise

R&D Update

CE Major Clinical Pipeline

Terminology of HER2

DS-8201: Clinical Program

DS-8201: P1 Study Design

DS-8201：P1 Study Demographic (5.4, 6.4mg/kg）

DS-8201: P1 Study Efficacy(1)

DS-8201: P1 Study Efficacy(2)

DS-8201: P1 Study Safety(1)

DS-8201: P1 Study Safety(2)

DS-8201: HER2-Low Breast Cancer

Redefined HER2 Subtype

DS-8201: Target of HER2-Low P3 Study

U3-1402: BC P1/2 Study Overview

U3-1402: BC P1/2 Study Efficacy

U3-1402: BC P1/2 Study Safety

ADC Franchises: Next Data Point

7th Project in ADC Franchise (with Glycotope)

Summary of ADC Franchise

Quizartinib: AML Treatment and QuANTUM Studies

Quizartinib: QuANTUM-R Study Design

Quizartinib: QuANTUM-R Study Efficacy(1)

Quizartinib: QuANTUM-R Study Efficacy(2)

Quizartinib: QuANTUM-R Study QT Prolongation

Pexidartinib: TGCT Overview

Pexidartinib: ENLIVEN Study Efficacy

Pexidartinib: Extreme Example of Effective Treatment

Pexidartinib: ENLIVEN Study Safety

Summary of Quizartinib and Pexidartinib

DS R&D Day 2018

Appendix

FY2018 R&D Milestone Events

Major R&D Pipeline (Oncology)

Major R&D Pipeline (SM/Vaccine)

Out-licensing Projects

Abbreviations

@

Q&A

• Q&A 1

• Q&A 2

• Q&A 3

• Q&A 4

• Q&A 5

• Q&A 6